Tribute Pharmaceuticals Canada Inc. (TBUFF) 0.6700 $TBUFF
Tribute Pharmaceuticals Reports Full Year 2013 Results and Lays the Groundwork for Future Growth
Marketwire - Mon Mar 31, 6:03AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(OTCBB: TBUFF)(PINKSHEETS: TBUFF) ("Tribute" or the "Company"
, a Canadian specialty pharmaceutical company engaged in the acquisition, licensing, development and promotion of healthcare products in Canada and the United States, today announced financial results for its fiscal year ending December 31, 2013. In this press release, all dollar amounts are expressed in Canadian currency (unless otherwise noted) and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).
CAMBIA(R) Update From Tribute Pharmaceuticals
Marketwire - Fri Dec 20, 7:01AM CST
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF) (OTCBB: TBUFF) (PINKSHEETS: TBUFF) ("Tribute" or the "Company" , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada, today commented on the recent acquisition of CAMBIA(R) (diclofenac potassium for oral solution) by Depomed, Inc. (NASDAQ: DEPO). Depomed, Inc. ("Depomed" announced earlier this week that it had acquired the United States and Canadian rights to CAMBIA(R) (diclofenac potassium for oral solution) from Nautilus Neurosciences, Inc. ("Nautilus" of Bedminster, NJ. For a complete copy of Depomed's recent press release please visit www.depomed.com.
Tribute Pharmaceuticals Announces Solid Growth in Third Quarter 2013 and Bezalip US IND Cleared by FDA
Marketwire - Thu Nov 14, 7:03AM CST
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(OTCBB: TBUFF)(PINKSHEETS: TBUFF) ("Tribute" or "the Company" , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada, today announced financial results for its fiscal 2013 third quarter ending September 30, 2013. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).
TRIBUTE PHARMA'S Investigational New Drug Application for Bezalip(R) SR Cleared by the US Food and Drug Administration
Marketwire - Mon Nov 11, 7:01AM CST
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(OTCBB: TBUFF)(PINKSHEETS: TBUFF) ("Tribute" or the "Company" , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada, today announced that on September 27, 2013 an Investigational New Drug application ("IND" was submitted to the US Food and Drug Administration ("FDA" setting out the proposed development program for Bezalip(R) SR (bezafibrate) tablets in patients with severe hypertriglyceridemia (SHTG). This IND has been cleared by the FDA. According to the National Cholesterol Education Program (NCEP) expert panel, reduction of triglyceride levels (a type of fat) in patients with SHTG (fasting triglyceride levels above 500 mg/dl) is paramount to avoid the development of acute pancreatitis, a condition which can be life threatening. Many cases of hypertriglyceridemia are associated with disorders of triglyceride metabolism. These include diabetes mellitus, obesity, alcohol use and pregnancy, amongst others. Many of these conditions are associated with irregularities in how the body responds to insulin, including insulin deficiency, and insulin resistance. Consequently, pancreatitis associated with hypertriglyceridemia often presents on a background of poorly managed diabetes. Bezalip(R) SR is a well- established triglyceride lowering medicine which works in a unique way compared to other drugs used to treat cholesterol and triglycerides. Tribute's development program has been based on guidance provided by the FDA during an end of Phase II meeting held in March 2012. The Company intends to submit a Special Protocol Assessment to the FDA at its earliest convenience that incorporates all substantial scientific issues currently available to establish safety and efficacy as part of the development program.
OTC Daily Alert Stock Watch - Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)
WorldStockWire - Sat Sep 07, 12:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Tribute Pharmaceuticals Announces Double Digit Growth in Second Quarter 2013
Marketwire - Fri Aug 09, 8:52AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(OTCBB: TBUFF)(PINKSHEETS: TBUFF) ("Tribute" or "the Company" , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada, today announced financial results for its fiscal 2013 second quarter ending June 30, 2013. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).
Tribute Pharmaceuticals Announces Double Digit Growth in First Quarter 2013
Marketwire - Tue May 14, 6:31AM CDT
Tribute Pharmaceuticals Canada Inc. (formerly Stellar Pharmaceuticals Inc.) (OTCQB: TBUFF)(OTCBB: TBUFF)(PINKSHEETS: TBUFF) ("Tribute" or "the Company" , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada, today announced financial results for its fiscal 2013 first quarter ending March 31, 2013. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).
Tribute Pharmaceuticals Reports 2012 Year-End Results with Strong Revenue Growth
Marketwire - Thu Mar 21, 6:31AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(OTCBB: TBUFF) ("Tribute" or "the Company" , a Canadian specialty pharmaceutical company, today announced financial results for the year ended December 31, 2012. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).
Tribute Pharmaceuticals Expands Previously Announced Financing to Raise $4.6 Million
Marketwire - Fri Mar 15, 6:31AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(OTCBB: TBUFF)(PINKSHEETS: TBUFF) ("Tribute" or "the Company" , a Canadian specialty pharmaceutical company, today announced it has closed the second and final tranche of its privately placement of securities for aggregate gross proceeds of an additional US$1.2 million with private investors who are unaffiliated with the Company. These funds were raised in addition to a first tranche of securities sold for aggregate gross proceeds of US$3.4 million which included participation from, among others, the Company's Chief Executive Officer, Chief Financial Officer and certain members of its Board of Directors (see press release dated March 4, 2013). The three tranches together total approximately US$4.6 million.
SJ Strategic Investments LLC announces acquisition of securities of Tribute Pharmaceuticals Inc.
CNW Group - Tue Mar 05, 11:13AM CST
SJ Strategic Investments LLC ("SJ" , a private family owned investment vehicle, focusing on both private and public pharmaceutical company investments, today announced that it has acquired an additional 1,250,000 common shares ("Common Shares" of Tribute Pharmaceuticals Canada Inc. ("Tribute" (OTC: TBUFF) at a price of $0.40 per Common Share and acquired 625,000 series A warrants of Tribute ("Series A Warrants" and 625,000 series B warrants of Tribute ("Series B Warrants", and together with the Series A Warrants, the "Warrants" in a private placement of securities by Tribute (collectively, the "Offering" .
Tribute Pharmaceuticals Raises $3,400,000 With Strong Participation from Board and Management
Marketwire - Mon Mar 04, 6:31AM CST
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(OTCBB: TBUFF)(PINKSHEETS: TBUFF) ("Tribute" or "the Company" , a Canadian specialty pharmaceutical company, today announced it has raised approximately US$3.4 million through a private placement with private investors including the Company's Chief Executive Officer, Chief Financial Officer and most members of its Board of Directors. Insiders' investments accounted for over 50% of the gross proceeds raised at a price per Unit (as defined below) of $0.40, a premium over Friday's closing share price. The Company is also pleased to announce that two of its investors in this raise are former chief executive officers of large US specialty pharmaceutical companies. Use of proceeds from the private placement include the further funding of promotion for existing products such as Cambia(R), repayment of indebtedness, working capital and pending business development initiatives.
Tribute Pharmaceuticals Reports Full Year 2013 Results and Lays the Groundwork for Future Growth
Marketwire - Mon Mar 31, 6:03AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(OTCBB: TBUFF)(PINKSHEETS: TBUFF) ("Tribute" or the "Company"
, a Canadian specialty pharmaceutical company engaged in the acquisition, licensing, development and promotion of healthcare products in Canada and the United States, today announced financial results for its fiscal year ending December 31, 2013. In this press release, all dollar amounts are expressed in Canadian currency (unless otherwise noted) and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP). CAMBIA(R) Update From Tribute Pharmaceuticals
Marketwire - Fri Dec 20, 7:01AM CST
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF) (OTCBB: TBUFF) (PINKSHEETS: TBUFF) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada, today commented on the recent acquisition of CAMBIA(R) (diclofenac potassium for oral solution) by Depomed, Inc. (NASDAQ: DEPO). Depomed, Inc. ("Depomed" announced earlier this week that it had acquired the United States and Canadian rights to CAMBIA(R) (diclofenac potassium for oral solution) from Nautilus Neurosciences, Inc. ("Nautilus" of Bedminster, NJ. For a complete copy of Depomed's recent press release please visit www.depomed.com. Tribute Pharmaceuticals Announces Solid Growth in Third Quarter 2013 and Bezalip US IND Cleared by FDA
Marketwire - Thu Nov 14, 7:03AM CST
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(OTCBB: TBUFF)(PINKSHEETS: TBUFF) ("Tribute" or "the Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada, today announced financial results for its fiscal 2013 third quarter ending September 30, 2013. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP). TRIBUTE PHARMA'S Investigational New Drug Application for Bezalip(R) SR Cleared by the US Food and Drug Administration
Marketwire - Mon Nov 11, 7:01AM CST
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(OTCBB: TBUFF)(PINKSHEETS: TBUFF) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada, today announced that on September 27, 2013 an Investigational New Drug application ("IND" was submitted to the US Food and Drug Administration ("FDA" setting out the proposed development program for Bezalip(R) SR (bezafibrate) tablets in patients with severe hypertriglyceridemia (SHTG). This IND has been cleared by the FDA. According to the National Cholesterol Education Program (NCEP) expert panel, reduction of triglyceride levels (a type of fat) in patients with SHTG (fasting triglyceride levels above 500 mg/dl) is paramount to avoid the development of acute pancreatitis, a condition which can be life threatening. Many cases of hypertriglyceridemia are associated with disorders of triglyceride metabolism. These include diabetes mellitus, obesity, alcohol use and pregnancy, amongst others. Many of these conditions are associated with irregularities in how the body responds to insulin, including insulin deficiency, and insulin resistance. Consequently, pancreatitis associated with hypertriglyceridemia often presents on a background of poorly managed diabetes. Bezalip(R) SR is a well- established triglyceride lowering medicine which works in a unique way compared to other drugs used to treat cholesterol and triglycerides. Tribute's development program has been based on guidance provided by the FDA during an end of Phase II meeting held in March 2012. The Company intends to submit a Special Protocol Assessment to the FDA at its earliest convenience that incorporates all substantial scientific issues currently available to establish safety and efficacy as part of the development program. OTC Daily Alert Stock Watch - Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)
WorldStockWire - Sat Sep 07, 12:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Tribute Pharmaceuticals Announces Double Digit Growth in Second Quarter 2013
Marketwire - Fri Aug 09, 8:52AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(OTCBB: TBUFF)(PINKSHEETS: TBUFF) ("Tribute" or "the Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada, today announced financial results for its fiscal 2013 second quarter ending June 30, 2013. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP). Tribute Pharmaceuticals Announces Double Digit Growth in First Quarter 2013
Marketwire - Tue May 14, 6:31AM CDT
Tribute Pharmaceuticals Canada Inc. (formerly Stellar Pharmaceuticals Inc.) (OTCQB: TBUFF)(OTCBB: TBUFF)(PINKSHEETS: TBUFF) ("Tribute" or "the Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada, today announced financial results for its fiscal 2013 first quarter ending March 31, 2013. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP). Tribute Pharmaceuticals Reports 2012 Year-End Results with Strong Revenue Growth
Marketwire - Thu Mar 21, 6:31AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(OTCBB: TBUFF) ("Tribute" or "the Company"
, a Canadian specialty pharmaceutical company, today announced financial results for the year ended December 31, 2012. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP). Tribute Pharmaceuticals Expands Previously Announced Financing to Raise $4.6 Million
Marketwire - Fri Mar 15, 6:31AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(OTCBB: TBUFF)(PINKSHEETS: TBUFF) ("Tribute" or "the Company"
, a Canadian specialty pharmaceutical company, today announced it has closed the second and final tranche of its privately placement of securities for aggregate gross proceeds of an additional US$1.2 million with private investors who are unaffiliated with the Company. These funds were raised in addition to a first tranche of securities sold for aggregate gross proceeds of US$3.4 million which included participation from, among others, the Company's Chief Executive Officer, Chief Financial Officer and certain members of its Board of Directors (see press release dated March 4, 2013). The three tranches together total approximately US$4.6 million. SJ Strategic Investments LLC announces acquisition of securities of Tribute Pharmaceuticals Inc.
CNW Group - Tue Mar 05, 11:13AM CST
SJ Strategic Investments LLC ("SJ"
, a private family owned investment vehicle, focusing on both private and public pharmaceutical company investments, today announced that it has acquired an additional 1,250,000 common shares ("Common Shares" of Tribute Pharmaceuticals Canada Inc. ("Tribute" (OTC: TBUFF) at a price of $0.40 per Common Share and acquired 625,000 series A warrants of Tribute ("Series A Warrants" and 625,000 series B warrants of Tribute ("Series B Warrants", and together with the Series A Warrants, the "Warrants" in a private placement of securities by Tribute (collectively, the "Offering" . Tribute Pharmaceuticals Raises $3,400,000 With Strong Participation from Board and Management
Marketwire - Mon Mar 04, 6:31AM CST
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(OTCBB: TBUFF)(PINKSHEETS: TBUFF) ("Tribute" or "the Company"
, a Canadian specialty pharmaceutical company, today announced it has raised approximately US$3.4 million through a private placement with private investors including the Company's Chief Executive Officer, Chief Financial Officer and most members of its Board of Directors. Insiders' investments accounted for over 50% of the gross proceeds raised at a price per Unit (as defined below) of $0.40, a premium over Friday's closing share price. The Company is also pleased to announce that two of its investors in this raise are former chief executive officers of large US specialty pharmaceutical companies. Use of proceeds from the private placement include the further funding of promotion for existing products such as Cambia(R), repayment of indebtedness, working capital and pending business development initiatives. 
